<DOC>
	<DOCNO>NCT01817322</DOCNO>
	<brief_summary>To demonstrate cyclosporine-sparing immunosuppression standard dose Enteric-Coated Mycophenolate Sodium would preserve renal graft function transplantation without increase incidence adverse event , biopsy confirm acute rejection , local systemic infection , bone marrow suppression .</brief_summary>
	<brief_title>Kidney Graft Function Under Immunosuppression Strategies</brief_title>
	<detailed_description>This clinical investigation open-label , prospective , multi-center , 1:1 randomize comparative , longitudinal , investigator-initiated study . Patients end-stage renal disease assess eligibility , randomize use random number table one two group prior kidney transplantation . Immunosuppression consist Cyclosporine ( Neoral® ) , Methylprednisolone OR prednisone OR deflazacort ( Brand name designate ) Enteric-Coated Mycophenolate Sodium ( Myfortic® ) . Basilixumab ( Simulect® ) give prior transplant 4 day transplantation . The Enteric-Coated Mycophenolate Sodium give orally dose 720 mg BID Group A ( investigational ) 360 mg BID Group B ( comparator ) , start two day transplantation , show figure . Cyclosporine give orally dose 10 mg/Kg/day start day transplantation . Within month transplantation , dose drug individually adjust goal trough blood level 100 ng/mL 200 ng/mL Group A 200 ng/mL 300 ng/mL Group B , display table . From month 2 month post-transplantation , target blood trough level cyclosporine reduce 75 ng/mL 150 ng/mL Group A 150 ng/mL 250 ng/mL Group B . From 2 month 4 month post-transplantation , reduce 50 ng/mL 125 ng/mL Group A 125 ng/mL 200 ng/mL Group B . After 4 month post-transplantation , reduce 50 ng/mL 100 ng/mL Group A 100 ng/mL 200 ng/mL Group B .</detailed_description>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Deflazacort</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Male female patient endstage renal disease age 20 65 year undergoing primary kidney transplantation 2 . Kidney recipient transplant kidney decease live donor age 15 65 year 3 . Patients give write informed consent participate study 1. multiorgan recipient , dual kidney recipient previous transplant recipient organs include kidney , bone marrow , stem cell . 2 . Recipients transplant kidney nonheart beat donor , ABO incompatible donor , lymphocyte crossmatch positive donor 3 . Patients history malignancy within last five year , except successfully excise squamous basal cell carcinoma skin . 4 . Patients hypersensitivity Mycophenolate sodium , Mycophenolate acid Mycophenolate Mofetil excipients . 5 . Patient HGPRT ( Hypoxanthin eguanine phosphoribosyltransferas ) LeschNyhan syndrome kelleySeegmiller syndrome . 6 . Patients test positive HIV , HCV HBV surface antigen . 7 . Recipients organs donor test positive HBsAg , HCV , HIV 8 . Patients know hypersensitivity cyclosporine component formulation 9 . Patients applicable contradiction Sandimune Neoral 10 . Patients receive investigational drug within 30 day prior study entry . 11 . Females childbearing potential planning become pregnant , pregnant and/or lactating , unwilling use effective mean contraception . 12 . Existence surgical medical condition , current transplant , opinion investigator might significantly alter absorption , distribution , metabolism excretion study medication , and/or presence severe diarrhea , active peptic ulcer disease , uncontrolled diabetes mellitus . 13 . Evidence drug , alcohol abuse , and/or psychiatric illness within last 6 month prior study enroll 14 . At time screen evaluation study , patient platelet count &lt; 50,000/mm3 , absolute neutrophil count &lt; 1,500/mm3 , white blood cell count &lt; 4,500/mm3 , patient abnormal liver profile ALT , AST Alk Phos total bilirubin &gt; 3 time upper normal limit .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>kidney transplantation</keyword>
</DOC>